Diligence memo · auto-generated · as of July 2, 2026
Htg Molecular Diagnostics, Inc
Htg Molecular Diagnostics, Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Htg Molecular Diagnostics, Inc operates in Medical Devices, based in TUCSON.
Sub-sector tags: medical-devices.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Htg Molecular Diagnostics, Inc has raised $65M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2015-01-14.
Most recent recorded round closed around 2022-03-21.
Valuation (modeled)modeled
Provath models Htg Molecular Diagnostics, Inc at approximately $110M (range $17M–$306M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.69× the median modeled value of Series B Medical Devices companies in 2022–2024 (5 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Medical Devices peers (233 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Proxim Diagnostics Corp, Eximis Surgical Inc., EarliTec Diagnostics, Inc., Zenflow, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.